Skip to content
2000
image of The Rising Impact of HPV Infection in the Antiretroviral Therapy (ART) Era

Abstract

Introduction

Since the introduction of antiretroviral therapy (ART), non-AIDS malignancies—particularly anal cancer—have increased in people living with HIV (PLHIV). However, associated risk factors and disease progression remain poorly defined.

Material and Methods

This retrospective observational study analysed PLHIV who developed anal cancer between 2000 and 2021 at a third-level university hospital. Epidemiological, immunological, and microbiological factors, as well as disease management and outcomes, were assessed.

Results

A total of 38 patients were included, 95% of whom were men, with an incidence rate of 105 cases per 100,000 person-years. The median CD4 nadir was 169 cells/μl, with 60% of patients having a CD4 nadir <200 cells/μl, and 93.3% had a CD4/CD8 ratio <0.4. HPV infection was documented in 100% of tested patients (35/38), and 50% presented with advanced tumor stages. At 2 years post-diagnosis, 66% achieved complete remission, while 13.2% had a recurrence. Long-term tumor-related mortality was 15%, with an overall survival of 66%.

Discussion

A significant number of patients presented with advanced-stage anal cancer and ongoing immunosuppression, emphasising the need for earlier detection and better follow-up. Despite guidelines, screening participation remains low, highlighting the importance of multidisciplinary care and targeted prevention strategies in high-risk PLHIV populations. However, as a retrospective single-centre study with a limited sample size, our findings may be affected by information and selection bias, restricting broader applicability.

Conclusion

Co-infection with HIV and HPV and low CD4 nadir were common features in these patients. HPV prevention and anal dysplasia screening are crucial to reducing this emerging condition.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/chr/10.2174/011570162X381694250925045507
2025-10-14
2025-12-05

  • From This Site

    /content/journals/chr/10.2174/011570162X381694250925045507
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Bonnet F. Burty C. Lewden C. Changes in cancer mortality among HIV-infected patients: The Mortalité 2005 Survey. Clin. Infect. Dis. 2009 48 5 633 639 10.1086/596766 19202627
    [Google Scholar]
  2. Survival after introduction of HAART in people with known duration of HIV-1 infection. Lancet 2000 355 9210 1158 1159 10.1016/S0140‑6736(00)02069‑9 10791383
    [Google Scholar]
  3. Lewden C. Salmon D. Morlat P. Causes of death among HIV-infected adults in the era of potent antiretroviral therapy: Emerging role of hepatitis and cancers, persistent role of AIDS. Int. J. Epidemiol. 2005 34 1 121 130 10.1093/ije/dyh307 15561752
    [Google Scholar]
  4. Yanik E.L. Napravnik S. Cole S.R. Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence. AIDS 2014 28 7 979 987 10.1097/QAD.0000000000000167 24681415
    [Google Scholar]
  5. Engels E.A. Non-0002030-defining malignancies in HIV-infected persons: Etiologic puzzles, epidemiologic perils, prevention opportunities. AIDS 2009 23 8 875 885 10.1097/QAD.0b013e328329216a 19349851
    [Google Scholar]
  6. Franceschi S. Lise M. Clifford G.M. Changing patterns of cancer incidence in the early- and late-HAART periods: The Swiss HIV Cohort Study. Br. J. Cancer 2010 103 3 416 422 10.1038/sj.bjc.6605756 20588274
    [Google Scholar]
  7. Dubrow R. Silverberg M.J. Park L.S. Crothers K. Justice A.C. HIV infection, aging, and immune function. Curr. Opin. Oncol. 2012 24 5 506 516 10.1097/CCO.0b013e328355e131 22759737
    [Google Scholar]
  8. Machalek D.A. Poynten M. Jin F. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: A systematic review and meta-analysis. Lancet Oncol. 2012 13 5 487 500 10.1016/S1470‑2045(12)70080‑3 22445259
    [Google Scholar]
  9. Workowski K.A. Bachmann L.H. Chan P.A. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm. Rep. 2021 70 4 1 187 10.15585/mmwr.rr7004a1 34292926
    [Google Scholar]
  10. Hessol N.A. Pipkin S. Schwarcz S. Cress R.D. Bacchetti P. Scheer S. The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am. J. Epidemiol. 2007 165 10 1143 1153 10.1093/aje/kwm017 17344204
    [Google Scholar]
  11. Kelly H. Chikandiwa A. Alemany Vilches L. Palefsky J.M. de Sanjose S. Mayaud P. Association of antiretroviral therapy with anal high-risk human papillomavirus, anal intraepithelial neoplasia, and anal cancer in people living with HIV: A systematic review and meta-analysis. Lancet HIV 2020 7 4 e262 e278 10.1016/S2352‑3018(19)30434‑5 32109408
    [Google Scholar]
  12. Stier E.A. Clarke M.A. Deshmukh A.A. International anal neoplasia society’s consensus guidelines for anal cancer screening. Int. J. Cancer 2024 154 10 1694 1702 10.1002/ijc.34850 38297406
    [Google Scholar]
  13. Palefsky J.M. Lee J.Y. Jay N. Treatment of anal high-grade squamous intraepithelial lesions to prevent anal cancer. N. Engl. J. Med. 2022 386 24 2273 2282 10.1056/NEJMoa2201048 35704479
    [Google Scholar]
  14. Bosman F. Carneiro F. Hruban R. Theise N. WHO Classification of Tumours of the Digestive System. Geneva WHO Press 2010
    [Google Scholar]
  15. Sendagorta Cudós E. Sotomayor C. Masia Canuto M. Incidence of anal cancer and related risk factors in hiv-infected patients enrolled in the national prospective spanish cohort CoRIS. Dis. Colon Rectum 2023 66 12 e1186 e1194 10.1097/DCR.0000000000002940 37556018
    [Google Scholar]
  16. Ye Y. Burkholder G.A. Mukherjee A. A 12-year retrospective evaluation of anal pre-cancerous lesions and cancer in people living with HIV-1 infection in the Southeastern U.S. Infect. Agent. Cancer 2021 16 1 14 10.1186/s13027‑021‑00354‑7 33596943
    [Google Scholar]
  17. Pérez-González A. Cachay E. Ocampo A. Poveda E. Update on the epidemiological features and clinical implications of human papillomavirus infection (HPV) and human immunodeficiency virus (HIV) coinfection. Microorganisms 2022 10 5 1047 10.3390/microorganisms10051047 35630489
    [Google Scholar]
  18. Serrano-Villar S. Deeks S.G. CD4/CD8 ratio: An emerging biomarker for HIV. Lancet HIV 2015 2 3 e76 e77 10.1016/S2352‑3018(15)00018‑1 26424546
    [Google Scholar]
  19. Martínez-Sanz J. Díaz-Álvarez J. Cancio-Suarez R.M. Expanding HIV clinical monitoring: The role of CD4, CD8, and CD4/CD8 ratio in predicting non-AIDS events. EBioMedicine 2023 95 104773 10.1016/j.ebiom.2023.104773 37639938
    [Google Scholar]
  20. Ambrosioni J. Levi L. Alagaratnam J. Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023. HIV Med. 2023 24 11 1126 1136 10.1111/hiv.13542 37849432
    [Google Scholar]
  21. Karim A. Freeman M.J. Yang Q. Duration of Time CD4/CD8 ratio is below 0.5 is associated with progression to anal cancer in patients with HIV and high-grade dysplasia. Ann. Surg. Oncol. 2023 30 8 4737 4743 10.1245/s10434‑023‑13213‑z 36869915
    [Google Scholar]
  22. Milanés Guisado Y. Sotomayor C. Fontillón M. Incidence rate and risk factors for anal squamous cell carcinoma in a cohort of people living with HIV from 2004 to 2017: Implementation of a screening program. Dis. Colon Rectum 2022 65 1 28 39 10.1097/DCR.0000000000002218 34694279
    [Google Scholar]
  23. van der Zee R.P. Wit F.W.N.M. Richel O. Effect of the introduction of screening for cancer precursor lesions on anal cancer incidence over time in people living with HIV: A nationwide cohort study. Lancet HIV 2023 10 2 e97 e106 10.1016/S2352‑3018(22)00368‑X 36640800
    [Google Scholar]
  24. Deshmukh A.A. Suk R. Shiels M.S. Recent trends in squamous cell carcinoma of the anus incidence and mortality in the united states, 2001–2015. J. Natl. Cancer Inst. 2020 112 8 829 838 10.1093/jnci/djz219 31742639
    [Google Scholar]
  25. Ronco G. Dillner J. Elfström K.M. Efficacy of HPV-based screening for prevention of invasive cervical cancer: Follow-up of four European randomised controlled trials. Lancet 2014 383 9916 524 532 10.1016/S0140‑6736(13)62218‑7 24192252
    [Google Scholar]
  26. Park I.U. Palefsky J.M. Evaluation and management of anal intraepithelial neoplasia in HIV-negative and HIV-positive men who have sex with men. Curr. Infect. Dis. Rep. 2010 12 2 126 133 10.1007/s11908‑010‑0090‑7 20461117
    [Google Scholar]
  27. Spindler L. Etienney I. Abramowitz L. Screening for precancerous anal lesions linked to human papillomaviruses: French recommendations for clinical practice. Tech. Coloproctol. 2024 28 1 23 10.1007/s10151‑023‑02899‑8 38198036
    [Google Scholar]
  28. Athanasiou A. Bowden S. Paraskevaidi M. HPV vaccination and cancer prevention. Best Pract. Res. Clin. Obstet. Gynaecol. 2020 65 109 124 10.1016/j.bpobgyn.2020.02.009 32284298
    [Google Scholar]
  29. Palefsky J.M. Giuliano A.R. Goldstone S. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N. Engl. J. Med. 2011 365 17 1576 1585 10.1056/NEJMoa1010971 22029979
    [Google Scholar]
  30. Poynten I.M. Tabrizi S.N. Jin F. Vaccine-preventable anal human papillomavirus in Australian gay and bisexual men. Papillomavirus Res. 2017 3 80 84 10.1016/j.pvr.2017.02.003 28720461
    [Google Scholar]
  31. Vaccination against human papillomavirus (HPV) in risk groups. 2024 Available from:https://www.comunidad.madrid/ser-vicios/salud/vacunas-informacion-profesionales
    [Google Scholar]
/content/journals/chr/10.2174/011570162X381694250925045507
Loading
The Rising Impact of HPV Infection in the Antiretroviral Therapy (ART) Era
Bentham Science Publishers ; https://doi.org/10.2174/011570162X381694250925045507
/content/journals/chr/10.2174/011570162X381694250925045507
/content/journals/chr/10.2174/011570162X381694250925045507
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: AIDS ; screening ; HPV ; HIV ; dysplasia screening ; Anal cancer

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test